Compounds > plerixafor
Page last updated: 2024-08-24

plerixafor and Anemia, Cooley's

plerixafor has been researched along with Anemia, Cooley's in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's6 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Anagnostopoulos, A; Bouinta, A; Constantinou, V; Jonlin, E; Karponi, G; Kotta, K; Papayannopoulou, T; Stamatoyannopoulos, G; Tachynopoulou, V; Yannaki, E; Zervou, F1
Anagnostopoulos, A; Arsenakis, M; Athanasiou, E; Baliakas, P; Constantinou, V; Gkountis, A; Papayannopoulou, T; Psatha, N; Sgouramali, E; Siametis, A; Stamatoyannopoulos, G; Yannaki, E1
Adair, JE; Anagnostopoulos, A; Karponi, G; Kleanthous, M; Lederer, CW; Psatha, N; Rivière, I; Sadelain, M; Stamatoyannopoulos, G; Tsatalas, C; Yannaki, E; Zervou, F; Zogas, N1
Anagnostopoulos, A; Bouinta, A; Constantinou, VC; Karponi, G; Papayanni, PG; Stamatoyannopoulos, G; Yannaki, E; Zervou, F1
Aprile, A; Bellio, L; Cappellini, MD; Cassinerio, E; Ciceri, F; Ferrari, G; Frittoli, MC; Gentner, B; Lidonnici, MR; Mandelli, G; Marktel, S; Paleari, Y; Parisi, C; Spinelli, A; Zambelli, M; Zanaboni, L1
Anagnostopoulos, A; Athanassiadou, A; Batsis, I; Becker, P; Bouinta, A; Constantinou, V; Fassas, A; Jonlin, E; Kaloyannidis, P; Karponi, G; Kotta, K; Papayannopoulou, T; Psatha, N; Stamatoyannopoulos, G; Tahynopoulou, V; Xagorari, A; Yannaki, E; Zervou, F1

Trials

2 trial(s) available for plerixafor and Anemia, Cooley's

ArticleYear
Poor stem cell harvest may not always be related to poor mobilization: lessons gained from a mobilization study in patients with β-thalassemia major.
    Transfusion, 2017, Volume: 57, Issue:4

    Topics: Adult; Benzylamines; beta-Thalassemia; Cyclams; Female; Genetic Therapy; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Leukapheresis; Male

2017
Hematopoietic stem cell mobilization for gene therapy of adult patients with severe β-thalassemia: results of clinical trials using G-CSF or plerixafor in splenectomized and nonsplenectomized subjects.
    Molecular therapy : the journal of the American Society of Gene Therapy, 2012, Volume: 20, Issue:1

    Topics: Adult; Antigens, CD34; Benzylamines; beta-Thalassemia; Cyclams; Female; Genetic Therapy; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Hydroxyurea; Immunophenotyping; Leukocyte Count; Leukocytosis; Male; Splenectomy; Treatment Outcome; Young Adult

2012

Other Studies

4 other study(ies) available for plerixafor and Anemia, Cooley's

ArticleYear
Hematopoietic stem cell mobilization for gene therapy: superior mobilization by the combination of granulocyte-colony stimulating factor plus plerixafor in patients with β-thalassemia major.
    Human gene therapy, 2013, Volume: 24, Issue:10

    Topics: Adult; Antigens, CD34; Benzylamines; beta-Thalassemia; Colony-Forming Units Assay; Combined Modality Therapy; Cyclams; Female; Genetic Therapy; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Male; Phenotype; Treatment Outcome; Young Adult

2013
Superior long-term repopulating capacity of G-CSF+plerixafor-mobilized blood: implications for stem cell gene therapy by studies in the Hbb(th-3) mouse model.
    Human gene therapy methods, 2014, Volume: 25, Issue:6

    Topics: Animals; Antigens, Differentiation; Benzylamines; beta-Thalassemia; Cell Cycle; Cell Survival; Combined Modality Therapy; Cyclams; Disease Models, Animal; Genes, Reporter; Genetic Vectors; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Lentivirus; Mice; Mice, Mutant Strains; Radiation Chimera; Recombinant Proteins; Splenectomy; Transplantation Chimera

2014
Plerixafor+G-CSF-mobilized CD34+ cells represent an optimal graft source for thalassemia gene therapy.
    Blood, 2015, Jul-30, Volume: 126, Issue:5

    Topics: Animals; Antigens, CD34; Benzylamines; beta-Globins; beta-Thalassemia; Cyclams; Gene Dosage; Gene Expression; Genetic Therapy; Genetic Vectors; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Heterocyclic Compounds; Heterografts; Humans; Mice; Mice, Knockout; Transplantation, Autologous

2015
Plerixafor and G-CSF combination mobilizes hematopoietic stem and progenitors cells with a distinct transcriptional profile and a reduced
    Haematologica, 2017, Volume: 102, Issue:4

    Topics: Animals; Antigens, CD34; Benzylamines; beta-Thalassemia; Cell Cycle Proteins; Chemokine CXCL12; Cyclams; Drug Combinations; Endonucleases; Gene Expression Profiling; Gene Expression Regulation; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Immunophenotyping; Leukapheresis; Mesenchymal Stem Cells; Mice; Protein Binding; Receptors, CXCR4; Signal Transduction; Stem Cell Niche

2017